China Tightens Clinical Study Grip In Sweeping Biosecurity Law Proposal
From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.
You may also be interested in...
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.
After proposing a sweeping biosecurity law in May, China is facing pressure from European governments for potentially posing severe restrictions on key sectors such as life sciences and biological research.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.